Perjeta Approved for Advanced Breast Cancer
MONDAY, June 11 (HealthDay News) — Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.